FEDERAL COURT OF AUSTRALIA
Bright v Femcare Limited [2001] FCA 1477
PROCEDURE – representative proceedings under Pt IVA of the Federal Court of Australia Act 1976 (Cth) (“the Act”)– whether proceedings satisfy the criteria in s 33C of the Act - whether there are substantial common issues of fact or law – whether the Court ought to make an order pursuant to s 33N of the Act that the proceeding no longer continue under Pt IVA of the Act
Federal Court of Australia Act 1976 (Cth), s 33C, s 33N
Silkfield Pty Ltd v Wong (1998) 90 FCR 152 at 157 – 158 referred to
Murphy v Overton Investments Pty Ltd [1999] FCA 1123 at [67], [80] referred to
Vasram v AMP Life Limited [2000] FCA 1676 at [14] referred to
Murphy v Overton Investments Pty Ltd [1999] FCA 689 at [15] referred to
Qantas Airways v Cameron (1996) 66 FCR 246 at 251 252, 293 referred to
Wong v Silkfield Pty Ltd (1999) 199 CLR 255 followed
Campomar Sociedad, Limitada v Nike International Ltd (2000) 169 ALR 677 at 704 [103] referred to
Fraser v NRMA Holdings Ltd (1995) 55 FCR 452 at 467 referred to
Ryan v Great Lakes Council (1998) 155 ALR 447 at 456 referred to
ACCC v Giraffe World Australia Pty Ltd (1998) 84 FCR 512 at 534 referred toKERRIE BRIGHT v FEMCARE LIMITED & ANOR
N 410 of 1999STONE J
19 OCTOBER 2001
SYDNEY
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N 410 OF 1999
BETWEEN:
KERRIE BRIGHT
APPLICANTAND:
FEMCARE LIMITED
FIRST RESPONDENTENDOVASIVE PTY LIMITED
(ACN 061 512 132)
SECOND RESPONDENTJUDGE:
STONE J
DATE OF ORDER:
19 OCTOBER 2001
WHERE MADE:
SYDNEY
THE COURT ORDERS:
pursuant to s 33N of the Federal Court of Australia Act 1976 (Cth), that this proceeding no longer continue under Pt IVA of the Act.
THE COURT DIRECTS THAT:
1.the proceedings be stood over to a date to be advised; and
2.the parties file and serve any written submissions on the issue of costs by 2 November 2001.
Note: Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
N 410 OF 1999
BETWEEN:
KERRIE BRIGHT
APPLICANTAND:
FEMCARE LIMITED
FIRST RESPONDENTENDOVASIVE PTY LIMITED
(ACN 061 512 132)
SECOND RESPONDENT
JUDGE:
STONE J
DATE:
19 OCTOBER 2001
PLACE:
SYDNEY
REASONS FOR JUDGMENT
INTRODUCTION
On 10 May 1999, the applicant commenced representative proceedings under Pt IVA of the Federal Court of Australia Act 1976 (Cth) (“the Act”). The proceedings have already given rise to six judgments of this Court: (1999) 166 ALR 743 (constitutional validity of Pt IVA of the Act; affirmed on appeal, (2000) 100 FCR 331), (2000) 175 ALR 50 (third amended statement of claim struck out), [2000] FCA 1179 (issues relating to a subpoena addressed to the Therapeutic Goods Administration), [2000] FCA 1344 (issues relating to subpoenas addressed…
Keep reading for free
Create a free CaseChat account to read Bright v Femcare Limited and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2001] FCA 1477
- Decision Date
CaseChat Overview and Summary
The primary legal issues before the court were whether the claims could be effectively dealt with in a representative proceeding and whether the common issues would materially advance the determination of the individual claims. The court had to assess whether the proceeding would be efficient and in the interests of justice, considering the potential costs and whether the common issues were likely to be revisited in the context of each individual claim. Additionally, the court considered whether the mandatory requirements of the legislation had been met.
In reaching its conclusion, the court found that the representative proceeding was not an efficient or effective means of dealing with the claims due to the significant individual issues that would need to be revisited in each case. The common issues identified in the proceeding were either too general to materially advance the individual claims or would require re-evaluation in each individual context. The intertwining of common and individual issues would likely result in excessive costs if the proceeding continued under Pt IVA. Consequently, the court decided that the proceeding should not continue under Pt IVA, and it proposed to order that the proceeding be stood over for further directions. The court also noted that it would allow parties to make written submissions on costs, with an opportunity for any party to be heard if desired.
The court's decision was grounded in the recognition that while there were common issues among the group members' claims, these issues were not sufficiently developed to advance the resolution of individual claims. The potential for revisiting these issues in the context of each individual claim suggested that a representative proceeding would not be efficient. Therefore, the court concluded that it was in the interests of justice to discontinue the proceeding under Pt IVA and to manage the claims individually, potentially in another jurisdiction, to minimize costs and ensure effective resolution.
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Established by: STONE J
The statement of claim identifies three warnings that, it is alleged, both Femcare and Endovasive (after 1993) had a duty to give. They are:(a) the “calibration risk” warning;(b) the “regular check” warning; and (c) the “no servicing” warning.Calibration risk warning The calibration risk warning, is described as a clear and prominent warning to the effect that:·it is critical to the performance of an applicator that it be in calibration; ·an applicator might become out of calibration as a result of ordinary use or as a result of mishandling or vigorous handling; ·it cannot be predicted with precision how much use will cause an applicator to become out of calibration; ·the use of an out of calibration applicator increases the risk of ineffective sterilisation and therefore a Filshie applicator should be checked immediately before use; and·it is therefore important that hospitals and doctors have had a reliable means of checking whether an applicator is in calibration before using it. Femcare, it is alleged, did not give such a warning to its Australian distributors or instruct them to give such a warning to hospitals, doctors and subdistributors. Endovasive and other distributors did not give such a warning to hospitals or doctors. Doctors and hospitals had a reasonable or legitimate expectation that Femcare and Endovasive would give such a warning, or alternatively, it was misleading or deceptive for them not to do so, or alternatively, Femcare and Endovasive owed a duty to hospitals and doctors to give the warning.Regular check warning Similar allegations are made in relation to the regular check warning. This is a warning that, because of the propensity of an applicator to fall out of calibration and the impossibility of predicting the precise circumstances in which this might occur, it is essential that an applicator be regularly checked by Femcare or its authorised agent, that accurate records of use be kept and that applicators which have not been regularly checked, or of which records of use have not been kept, not be used in procedures. No servicing warning The no servicing warning is described as a clear and prominent warning incorporating the regular check warning and stating that Femcare or its agent has an available means of checking the calibration of an applicator and that hospitals and doctors are not providing applicators to Femcare or its agent for checking. The pleading makes allegations in relation to this warning which are substantially the same as those made in relation to the other two warnings. There is, however, one difference the materiality of which is not immediately obvious. The duty to give the no servicing warning, unlike the duty to give the other warnings, is pleaded as a duty owed to the applicant and group members as well as a duty owed to hospitals, doctors and (in the case of Femcare) Australian distributors and (in the case of Endovasive) Australian subdistributors.Misrepresentation In addition to the allegations of misrepresentation stemming from the failure to give warnings, the applicant also alleges positive misrepresentation. It is said that Femcare (since 1982) and Endovasive (since November 1993) have made what is described as the “safety representation”. This is a representation that the Filshie procedure was and would be a safe and effective method of female sterilisation. That representation is said to have been made both in the product literature accompanying the equipment and, by implication, from the fact of the sale and promotion of the Filshie equipment. The safety representation is alleged to have been made to doctors, hospitals, distributors and subdistributors and is alleged to have been inaccurate because it was not qualified by either the calibration risk warning or the regular service warning. Misleading and deceptive conduct